Pfizer to build R&D capacity in China

Related tags People's republic of china Merck kgaa

Pfizer will expand its clinical services and biomedical presence in China as part of a worldwide effort to develop its R&D infrastructure.

Working with the government, the US firm will partner with the Wuhan National Bioindustry Base Construction and Management office to establish a clinical R&D centre to provide support for ongoing trial programmes.

Allan Gabor, president of Pfizer’s operations in North Asia, said the unit “will be an integral part of Pfizer's global R&D operations while being closely aligned with the Chinese government's strategy on biopharmaceutical industry development​.”

Pfizer also unveiled plans to expand its existing R&D facility in Shanghai.

The US drug giant joins Germany’s Merck KGaA which, earlier this week, also announced plans for its own €150m ($224m) clinical R&D hub in Beijing​.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines